

Pharmacy Management Quality Drug Policy

SUBJECT: Non-Formulary Medication Exception Review Policy

POLICY NUMBER: PHARMACY-69

EFFECTIVE DATE: 01/2014

LAST REVIEW DATE: 04/01/2023

If the member's subscriber contract excludes coverage for a specific service or prescription drug, it is not covered under that contract. In such cases, medical or drug policy criteria are not applied. This drug policy applies to the following line/s of business:

Policy Application

Category:	<input checked="" type="checkbox"/> Commercial Group (e.g., EPO, HMO, POS, PPO)	<input type="checkbox"/> Medicare Advantage
	<input checked="" type="checkbox"/> On Exchange Qualified Health Plans (QHP)	<input type="checkbox"/> Medicare Part D
	<input checked="" type="checkbox"/> Off Exchange Direct Pay	<input checked="" type="checkbox"/> Essential Plan (EP)
	<input type="checkbox"/> Medicaid & Health and Recovery Plans (MMC/HARP)	<input checked="" type="checkbox"/> Child Health Plus (CHP)
	<input type="checkbox"/> Federal Employee Program (FEP)	<input type="checkbox"/> Ancillary Services
	<input type="checkbox"/> Dual Eligible Special Needs Plan (D-SNP)	

DESCRIPTION:

The closed formulary drug benefit provides high quality, cost-effective prescription drug coverage. The benefit provides coverage for most generic drugs and certain brand name medications. The Pharmacy and Therapeutics (P&T) Committee is made up of local community physicians and clinical pharmacists and is responsible for endorsing the closed formulary drug list. To determine if a drug should be covered under the closed formulary benefit, the P&T Committee completes an extensive review of the drugs in each therapeutic drug class to evaluate the clinical effectiveness, quality, and value. The drugs that are proven to be of high clinical quality as well as cost effective are selected to be covered.

It is understood there may be situations where a non-covered drug may be the only treatment option available to treat a member's condition effectively. For those select cases a physician may request a closed formulary coverage exception evaluation. This process is initiated by the prescribing physician completing a request form and submitting a letter of medical necessity along with objective supporting documentation for review. The request is reviewed within the timeframes afforded by law and the determination and rationale is communicated to the provider and member.

This policy does not cover the Medicare line of business.

POLICY:

For Fully Insured Closed Formulary contracts and select self-funded employer groups:

Coverage exceptions will only be granted in specific limited cases where it is documented:

1. Documentation that all formulary drugs, both brand and generic (including the exact generic equivalent if available) from the same therapeutic drug class have been tried and failed **AND**
2. Medical documentation must support at least one of the following for each of the failed products, in order to be eligible for a coverage exception:
 - Hypersensitivity (allergic reaction)
 - Severe indisputable drug intolerance
 - Clinical ineffectiveness

Pharmacy Management Quality Drug Policy

Non-Formulary Medication Exception Review Policy

For **Child Health Plus**:

Coverage exceptions will only be granted in specific limited cases where it is documented:

1. At least two (2) formulary drugs from the same therapeutic drug class must have been tried and failed **AND**
2. Medical documentation must support at least one of the following for each of the failed products, to be eligible for a coverage exception:
 - Hypersensitivity (allergic reaction)
 - Severe indisputable drug intolerance
 - Clinical ineffectiveness
3. Coverage for a brand name product with a generic equivalent requires a trial of two (2) other drugs, including the generic equivalent

POLICY GUIDELINES:

1. In addition to the requirements listed above, all requests for non-covered drugs will be reviewed to ensure they are being used for an appropriate indication and may be subject to an off-label review in accordance with our Off-Label Use of FDA Approved Drugs Policy (Pharmacy-32).
2. Unsupported physician statement of hypersensitivity reaction, severe drug intolerance or clinical ineffectiveness without clear clinical history, reaction and resolution will not be considered adequate documentation.
3. Approved formulary exceptions will allow a non-formulary brand name drug to be processed at the formulary brand copayment/coinsurance.
4. For a diagnosis of gender dysphoria, a trial of all (or 2) formulary alternatives will not be required, so long as the requested non-formulary drug is indicated or supported as part of a treatment regimen for gender dysphoria.
5. Clinical Review criteria related to gender dysphoria has been reviewed and approved by the New York State Office of Mental Health.

REQUEST PROCESS:

1. All requests for a formulary exception are reviewed by the Excellus Pharmacy Utilization Management staff following policy guidelines and considering any unique patient specific clinical information presented. A Medical Director or peer reviewer (pharmacist for self-funded plans) completes all denials.

2. **For all lines of business except Medicare:**

Standard approval time is one year. Exceptions to the standard timeframe may include situations where doses/treatments are limited to a certain time-period (i.e., short-term approval for bowel preps, acute antibiotic treatments)

3. **Timeframes:**

- a. **Fully Insured Closed Formulary contracts:**

For non-formulary requests, Standard (non-urgent) requests for a non-formulary drug will be completed within 72 hours.

For the expedited exceptions process, based on exigent circumstances that is defined as when an enrollee is suffering from a health condition that may seriously jeopardize the enrollee's life, health, or ability to regain maximum function or when an enrollee is undergoing a current course of treatment using a non-formulary drug, the health plan will make its

Pharmacy Management Quality Drug Policy

Non-Formulary Medication Exception Review Policy

coverage determination on such requests within no more than 24 hours after receiving them and continue to provide the drug for the duration of the exigency.

b. Self-Funded Commercial Closed non-formulary requests:

For non-formulary requests, standard (non-urgent) requests will be completed in 3 business days. Urgent (expedited) requests will be completed within 3 calendar days (72 hours) of receipt.

4. Notification:

Each formulary exception review will include a determination letter to the member and a fax to the physician. Depending on the benefit, an attempt is also made to contact the member and the provider by phone. If the determination is a denial, an Adverse Determination letter, which includes the Notice of Determination (NOD) is sent to the member. The prescriber receives a fax of the information. If the denial is for a review for a Fully Insured Closed Formulary contract, the issued letter will indicate that the decision is the final adverse determination and will provide instructions on how to submit for external appeal if necessary.

In the event of a denied request, the notification letter will include the following:

- Rationale for denial.
- Instructions on how to initiate an appeal.*
- Information on the right to obtain a copy of the review criteria.
- Instructions on how to have prescribing physician discuss case with clinical reviewer.
- *The documentation, in letter format, contains instructions regarding how to initiate standard, expedited, and external appeals. The phone numbers for Member Services, the New York State Department of Health, and the New York Department of Insurance are included in the written notification to members. Notices of adverse determinations to Medicaid members will also include fair hearing rights, aid continuing rights, and the members' right to contact the New York State Department of Health.

5. Lack of Medical Information:

If an exception request cannot be determined because of the failure to provide enough and appropriate medical information, then the provider and member are notified that the provider must produce certain requested information within 45 days for self-funded plans and Child Health Plus products. If the requested information is not provided within timeframes for consideration, the formulary exception request will be denied due to the failure to supply such information in a timely manner. The member and provider will be notified of the denial on this basis. Formulary Exceptions for Fully Insured Closed Formulary contracts will be completed within the 24- or 72-hour timeframe with the information obtainable within those timeframes. Provider outreach to collect required medical information is done by fax and by phone as appropriate.

UPDATES:

Date:	Revision:
04/01/2023	Revised
10/10/2022	Revised
7/11/22	Revised
2/18/2022	Revised
11/22/2021	Revised

Pharmacy Management Quality Drug Policy Non-Formulary Medication Exception Review Policy

2/11/2021	Revised
9/20	Revised
4/20	Revised
9/19	Revised
7/19	Revised
12/18	Revised
6/18	Revised
1/18	Revised
12/16	Revised
9/16	Revised
11/15	Revised
7/15	Revised
8/14	Revised
7/14	Created

VIOLATIONS:

Violation of this policy may result in disciplinary action, up to and including termination for employees, termination of vendor, contractors or consultants' contracts, or dismissal for interns and volunteers. Additionally, individuals may be subject to loss of access privileges and/or civil or criminal prosecution. The Health Plan is subject to action against the Certificate of Authority and/or civil monetary penalties per New York State Department of Health regulations.

EFFECT ON PREVIOUS POLICIES:

This policy supersedes any previous policy with respect to this subject matter approved or adopted by The Lifetime Healthcare Companies or its subsidiary or affiliates to which this policy applies.

At any time and without notice, the Corporation reserves the right to amend or establish its policies, requirements, and standards.

COMMITTEE APPROVAL HISTORY:

Date	Revision
11/17/2022	Review / P&T Committee Approval
9/16/2021	Reviewed/P&T Committee Approval
9/16/2020	P&T Committee Approval